Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 16, 2022

BUY
$0.72 - $2.93 $248,544 - $1.01 Million
345,200 New
345,200 $249,000
Q3 2020

Nov 13, 2020

SELL
$2.39 - $13.08 $71,700 - $392,400
-30,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$6.67 - $13.58 $200,100 - $407,400
30,000 New
30,000 $407,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $438M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Parallax Volatility Advisers, L.P. Portfolio

Follow Parallax Volatility Advisers, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.